NCT03754803View on ClinicalTrials.gov

Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

CompletedOBSERVATIONAL
Enrollment

376

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

May 6, 2024

Study Completion Date

May 6, 2024

Conditions
HIV Infections
Interventions
OTHER

HIV symptom distress module (SDM) questionnaire

The SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.

OTHER

HIV treatment satisfaction questionnaire (TSQ)

The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.

Trial Locations (18)

10243

GSK Investigational Site, Berlin

10629

GSK Investigational Site, Berlin

10777

GSK Investigational Site, Berlin

12163

GSK Investigational Site, Berlin

14057

GSK Investigational Site, Berlin

14059

GSK Investigational Site, Berlin

20146

GSK Investigational Site, Hamburg

20246

GSK Investigational Site, Hamburg

44787

GSK Investigational Site, Bochum

49090

GSK Investigational Site, Osnabrück

50668

GSK Investigational Site, Cologne

50674

GSK Investigational Site, Cologne

52062

GSK Investigational Site, Aachen

68161

GSK Investigational Site, Mannheim

80331

GSK Investigational Site, München

80335

GSK Investigational Site, München

80336

GSK Investigational Site, München

99427

GSK Investigational Site, Weimar

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

MUC Research GmbH
All Listed Sponsors
collaborator

MUC Research GmbH

OTHER

lead

ViiV Healthcare

INDUSTRY

NCT03754803 - Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany | Biotech Hunter | Biotech Hunter